PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Device: Enbrel 50 mg Prefilled SyringeDevice: Enbrel 50 mg Autoinjector
- First Posted Date
- 2007-04-12
- Last Posted Date
- 2013-03-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 640
- Registration Number
- NCT00459706
Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 609
- Registration Number
- NCT00457457
- Locations
- 🇬🇧
Pfizer Investigational Site, Bristol, United Kingdom
A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone
Phase 3
Completed
- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 960
- Registration Number
- NCT00457392
- Locations
- 🇬🇧
Pfizer Investigational Site, Yeovil, Somerset, United Kingdom
A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)
Phase 2
Withdrawn
- Conditions
- Diabetic RetinopathyDiabetes Mellitus
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00457470
A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)
Phase 1
Completed
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2009-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00457743
- Locations
- 🇯🇵
Pfizer Investigational Site, Chuo-ku, Tokyo, Japan
Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer
Phase 3
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 768
- Registration Number
- NCT00457691
- Locations
- 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Drug: Axitinib + Paclitaxel + Carboplatin (Cohort 1)Drug: Axitinib + Paclitaxel + Carboplatin (Cohort 2)Drug: Axitinib + Paclitaxel + Carboplatin (Cohort 3)Drug: Axitinib + Paclitaxel (Cohort 4)Drug: Axitinib + Docetaxel + Carboplatin (Cohort 4a)Drug: Axitinib + Docetaxel (Cohort 5)Drug: Axitinib + Capecitabine (Cohort 6)Drug: Axitinib + Capecitabine (Cohort 7)Drug: Axitinib + Gemcitabine + Cisplatin (Cohort 8)Drug: Axitinib + Pemetrexed + Cisplatin (Cohort 9)
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2012-04-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 102
- Registration Number
- NCT00454649
- Locations
- 🇪🇸
Pfizer Investigational Site, Madrid, Spain
A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease
Phase 1
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Biological: PF-04360365Drug: Placebo
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2009-10-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT00455000
- Locations
- 🇬🇧
Pfizer Investigational Site, Southampton, United Kingdom
Phase 1 Clinical Trial of Varenicline in Chinese Healthy Smoking Volunteers
Phase 1
Completed
- Conditions
- Smoking
- First Posted Date
- 2007-03-28
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT00452894
- Locations
- 🇨🇳
Pfizer Investigational Site, Beijing, China
Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
Terminated
- Conditions
- Cardiovascular DiseaseCerebrovascular Disorders
- First Posted Date
- 2007-03-28
- Last Posted Date
- 2008-02-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26784
- Registration Number
- NCT00452842
- Locations
- 🇺🇸
Pfizer Investigational Site, Clearwater, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath